A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy

Masashi Matsushima, Eiji Kikuchi, Takahiro Maeda, Jun Nakashima, Akitomo Sugawara, Toshiyuki Ando, Ryuichi Mizuno, Hirohiko Nagata, Akira Miyajima, Naoyuki Shigematsu, Mototsugu Oya

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: Few studies have evaluated changes in erectile function with time before and after prostate brachytherapy using the International Index of Erectile Function-15, a sensitive, validated tool for assessing male sexual dysfunction. In this prospective study we evaluated the natural history of erectile function after prostate brachytherapy without supplemental therapy (external beam radiotherapy, phosphodiesterase-5 inhibitors or androgen deprivation therapy) using the International Index of Erectile Function-15. Materials and Methods: We identified 119 patients who were followed at least 12 months after prostate brachytherapy between 2004 and 2010. Sexual and erectile function status were assessed before brachytherapy (baseline), and 3, 6, 12, 18, 24 and 36 months postoperatively using the International Index of Erectile Function-15. Results: Mean total International Index of Erectile Function-15 score, and scores on the erectile function, orgasmic function, sexual desire and intercourse satisfaction domains 3 months after brachytherapy were significantly lower than at baseline (p <0.05). They remained lower until 36 months after prostate brachytherapy. Erectile function was maintained 12 months after brachytherapy in 16 of the 48 men (33.3%) with a baseline erectile function domain score of 11 or greater. There was no significant difference in clinical features except the age of patients who maintained the erectile function domain score and their counterparts 12 months after brachytherapy. Multivariate analysis revealed that age 70 years or greater was the only predictive factor for deteriorating erectile function after brachytherapy (p = 0.035). Conclusions: Findings indicate a global decrease in all domains of the International Index of Erectile Function-15 score 12 months after prostate brachytherapy. Also, patient age may influence the preservation of brachytherapy related potency.

Original languageEnglish
Pages (from-to)1014-1018
Number of pages5
JournalJournal of Urology
Volume189
Issue number3
DOIs
Publication statusPublished - 2013 Mar

Fingerprint

Brachytherapy
Erectile Dysfunction
Longitudinal Studies
Prostate
Prostatic Neoplasms
Phosphodiesterase 5 Inhibitors
Coitus
Natural History
Androgens
Radiotherapy
Multivariate Analysis
Prospective Studies

Keywords

  • brachytherapy
  • erectile dysfunction
  • prostate
  • prostatic neoplasms
  • questionnaires

ASJC Scopus subject areas

  • Urology

Cite this

A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. / Matsushima, Masashi; Kikuchi, Eiji; Maeda, Takahiro; Nakashima, Jun; Sugawara, Akitomo; Ando, Toshiyuki; Mizuno, Ryuichi; Nagata, Hirohiko; Miyajima, Akira; Shigematsu, Naoyuki; Oya, Mototsugu.

In: Journal of Urology, Vol. 189, No. 3, 03.2013, p. 1014-1018.

Research output: Contribution to journalArticle

Matsushima, Masashi ; Kikuchi, Eiji ; Maeda, Takahiro ; Nakashima, Jun ; Sugawara, Akitomo ; Ando, Toshiyuki ; Mizuno, Ryuichi ; Nagata, Hirohiko ; Miyajima, Akira ; Shigematsu, Naoyuki ; Oya, Mototsugu. / A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy. In: Journal of Urology. 2013 ; Vol. 189, No. 3. pp. 1014-1018.
@article{33118cd4c4a148a79423cc5c5524b650,
title = "A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy",
abstract = "Purpose: Few studies have evaluated changes in erectile function with time before and after prostate brachytherapy using the International Index of Erectile Function-15, a sensitive, validated tool for assessing male sexual dysfunction. In this prospective study we evaluated the natural history of erectile function after prostate brachytherapy without supplemental therapy (external beam radiotherapy, phosphodiesterase-5 inhibitors or androgen deprivation therapy) using the International Index of Erectile Function-15. Materials and Methods: We identified 119 patients who were followed at least 12 months after prostate brachytherapy between 2004 and 2010. Sexual and erectile function status were assessed before brachytherapy (baseline), and 3, 6, 12, 18, 24 and 36 months postoperatively using the International Index of Erectile Function-15. Results: Mean total International Index of Erectile Function-15 score, and scores on the erectile function, orgasmic function, sexual desire and intercourse satisfaction domains 3 months after brachytherapy were significantly lower than at baseline (p <0.05). They remained lower until 36 months after prostate brachytherapy. Erectile function was maintained 12 months after brachytherapy in 16 of the 48 men (33.3{\%}) with a baseline erectile function domain score of 11 or greater. There was no significant difference in clinical features except the age of patients who maintained the erectile function domain score and their counterparts 12 months after brachytherapy. Multivariate analysis revealed that age 70 years or greater was the only predictive factor for deteriorating erectile function after brachytherapy (p = 0.035). Conclusions: Findings indicate a global decrease in all domains of the International Index of Erectile Function-15 score 12 months after prostate brachytherapy. Also, patient age may influence the preservation of brachytherapy related potency.",
keywords = "brachytherapy, erectile dysfunction, prostate, prostatic neoplasms, questionnaires",
author = "Masashi Matsushima and Eiji Kikuchi and Takahiro Maeda and Jun Nakashima and Akitomo Sugawara and Toshiyuki Ando and Ryuichi Mizuno and Hirohiko Nagata and Akira Miyajima and Naoyuki Shigematsu and Mototsugu Oya",
year = "2013",
month = "3",
doi = "10.1016/j.juro.2012.09.086",
language = "English",
volume = "189",
pages = "1014--1018",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - A prospective longitudinal survey of erectile dysfunction in patients with localized prostate cancer treated with permanent prostate brachytherapy

AU - Matsushima, Masashi

AU - Kikuchi, Eiji

AU - Maeda, Takahiro

AU - Nakashima, Jun

AU - Sugawara, Akitomo

AU - Ando, Toshiyuki

AU - Mizuno, Ryuichi

AU - Nagata, Hirohiko

AU - Miyajima, Akira

AU - Shigematsu, Naoyuki

AU - Oya, Mototsugu

PY - 2013/3

Y1 - 2013/3

N2 - Purpose: Few studies have evaluated changes in erectile function with time before and after prostate brachytherapy using the International Index of Erectile Function-15, a sensitive, validated tool for assessing male sexual dysfunction. In this prospective study we evaluated the natural history of erectile function after prostate brachytherapy without supplemental therapy (external beam radiotherapy, phosphodiesterase-5 inhibitors or androgen deprivation therapy) using the International Index of Erectile Function-15. Materials and Methods: We identified 119 patients who were followed at least 12 months after prostate brachytherapy between 2004 and 2010. Sexual and erectile function status were assessed before brachytherapy (baseline), and 3, 6, 12, 18, 24 and 36 months postoperatively using the International Index of Erectile Function-15. Results: Mean total International Index of Erectile Function-15 score, and scores on the erectile function, orgasmic function, sexual desire and intercourse satisfaction domains 3 months after brachytherapy were significantly lower than at baseline (p <0.05). They remained lower until 36 months after prostate brachytherapy. Erectile function was maintained 12 months after brachytherapy in 16 of the 48 men (33.3%) with a baseline erectile function domain score of 11 or greater. There was no significant difference in clinical features except the age of patients who maintained the erectile function domain score and their counterparts 12 months after brachytherapy. Multivariate analysis revealed that age 70 years or greater was the only predictive factor for deteriorating erectile function after brachytherapy (p = 0.035). Conclusions: Findings indicate a global decrease in all domains of the International Index of Erectile Function-15 score 12 months after prostate brachytherapy. Also, patient age may influence the preservation of brachytherapy related potency.

AB - Purpose: Few studies have evaluated changes in erectile function with time before and after prostate brachytherapy using the International Index of Erectile Function-15, a sensitive, validated tool for assessing male sexual dysfunction. In this prospective study we evaluated the natural history of erectile function after prostate brachytherapy without supplemental therapy (external beam radiotherapy, phosphodiesterase-5 inhibitors or androgen deprivation therapy) using the International Index of Erectile Function-15. Materials and Methods: We identified 119 patients who were followed at least 12 months after prostate brachytherapy between 2004 and 2010. Sexual and erectile function status were assessed before brachytherapy (baseline), and 3, 6, 12, 18, 24 and 36 months postoperatively using the International Index of Erectile Function-15. Results: Mean total International Index of Erectile Function-15 score, and scores on the erectile function, orgasmic function, sexual desire and intercourse satisfaction domains 3 months after brachytherapy were significantly lower than at baseline (p <0.05). They remained lower until 36 months after prostate brachytherapy. Erectile function was maintained 12 months after brachytherapy in 16 of the 48 men (33.3%) with a baseline erectile function domain score of 11 or greater. There was no significant difference in clinical features except the age of patients who maintained the erectile function domain score and their counterparts 12 months after brachytherapy. Multivariate analysis revealed that age 70 years or greater was the only predictive factor for deteriorating erectile function after brachytherapy (p = 0.035). Conclusions: Findings indicate a global decrease in all domains of the International Index of Erectile Function-15 score 12 months after prostate brachytherapy. Also, patient age may influence the preservation of brachytherapy related potency.

KW - brachytherapy

KW - erectile dysfunction

KW - prostate

KW - prostatic neoplasms

KW - questionnaires

UR - http://www.scopus.com/inward/record.url?scp=84873707040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873707040&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.09.086

DO - 10.1016/j.juro.2012.09.086

M3 - Article

C2 - 23017516

AN - SCOPUS:84873707040

VL - 189

SP - 1014

EP - 1018

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -